Organization · Venture Capital
SV Dementia Discovery Fund (DDF)
The Dementia Discovery Fund (DDF) is a venture capital fund focused on investing in companies developing novel therapeutics for dementia, including Alzheimer's Disease. With offices in London and Boston, it has raised over $600 million to address this significant medical need.
Overview
What SV Dementia Discovery Fund (DDF) does
What SV Dementia Discovery Fund (DDF) is
The Dementia Discovery Fund (DDF) is a venture capital fund focused on investing in companies developing novel therapeutics for dementia, including Alzheimer's Disease. With offices in London and Boston, it has raised over $600 million to address this significant medical need.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2015
- Approximate age
- About 11 years
- Structured capabilities
- Funder
- Last reviewed
- April 10, 2026
Official channels
Find SV Dementia Discovery Fund (DDF) elsewhere
Open the official website or a supported primary organization account.
Capability profile
SV Dementia Discovery Fund (DDF) as a funder
Investment thesis
Exclusively invests in novel disease-modifying therapeutics for all forms of dementia. Builds and backs early-stage biotech companies with deep scientific differentiation. Leverages pharma LP network for strategic partnerships and follow-on.
Focus narrative
DDF invests across the full spectrum of company and asset stages, targeting innovative projects informed by cutting-edge science that can significantly impact dementia patients. The fund's mandate includes interrogating novel hypotheses and expanding the breadth of targets and mechanisms in development for dementia therapies, starting from target identification.
Value beyond capital
DDF provides strategic support to its portfolio companies by leveraging its extensive network of pharmaceutical partners for collaborations and follow-on investments. The fund's focus on early-stage biotech ensures that it backs companies with deep scientific differentiation, enhancing their potential for success in the competitive landscape of dementia therapeutics.
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series B · Series C · Growth Equity
- Regions
- Europe · Global · North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 20
- Recorded notable exits
- Caraway Therapeutics
Portfolio context
DDF's portfolio includes notable companies such as Cerevance, which specializes in molecular analysis of specific cell types in human brain tissue; Therini Bio, focusing on therapies targeting inflammatory fibrin; and Alector Therapeutics, which has an AL002 antibody in Phase 2 for Alzheimer's. Other companies include Caraway Therapeutics, acquired by Merck, and NRG Therapeutics, which recently completed a GBP 50M Series B led by DDF.
Common questions
What to know about SV Dementia Discovery Fund (DDF)
Upseed classifies SV Dementia Discovery Fund (DDF) under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 10, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.